ViaDerma, Inc. (OTC Pink: VDRM) is a specialty pharmaceutical company that aims to deliver medicine by transdermal absorption. Shares of the pharmaceutical company are rallying 23.29%, through early trading on Wednesday, November 16, 2016. Over the past three months, ViaDerma, Inc., has seen average daily volume of over 2.5 million shares. However, nearly 33.6 million shares or dollar volume of $299,040, has already exchanged hands through early trading Wednesday.

ViaDerm, Inc. is rallying on Wednesday, after the company announced it has officially entered into the medical marijuana business. The company announced it has developed a topical, transdermal system that will feature the use of cannabinoids (CBDs) and tetrahydrocannabinol (THC) and even has a patent pending. Dr. Christopher Otiko, ViaDerma, Inc. founder and CEO, says the new product will allow the company to treat several different types of diseases and illnesses. Here is the full press release detailing of the new business venture:

ViaDerm, Inc. Press Release:

LOS ANGELES, CA–(Marketwired – November 14, 2016) – ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, announced today the Patent Pending use of its innovative transdermal system for the delivery of (CBD’s) Calanoids and (THC) Tetrahydrocannabinol for the treatment of several diseases. The transdermal system can deliver through topical skin absorption to localized areas and directly into the blood stream. The Patent application using the combination of CBD’s and THC with the delivery system was filed in 2014. The Patent Pending transdermal system can deliver medications and nutrients into the body through the skin. For example, a person with a migraine headache can place the CBD and THC combined with the delivery compound and apply to the neck with immediate absorption into the bloodstream through the corroded artery. ViaDerma, Inc. is also in the clinical testing stages of an anti-aging topical solution, topical pain medication, a topical for male-pattern baldness, and a topical designed to boost male libido.

On November 8th, medical and recreational marijuana was passed in several states that voted on medical marijuana provisions, in what is turning out to be, the biggest electoral victory for marijuana reform since 2012. The use of CBD’s is known for the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Cohn’s disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis.

ViaDerma also has Viabecline, a topical liquid tetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery system that can convert oral medication active ingredients into topical drugs. The drug is FDA-registered as a first aid antibiotic to help prevent skin infection in minor cuts, scrapes, and burns, but importantly, has also shown to be effective in fighting more harmful forms of staphylococcus aureus infections, which are commonly known as ‘staph infections.’ Without the introduction of novel antibiotic treatments, infections can spread and sometimes become life threatening.

Market for the following Drugs:

Topical antibiotics- $6 billion/year

Toenail antifungal drugs- $3 billion/year

Diabetic amputations- $3 billion/year

Global acne- $2.8 million in 2009, estimates of $3.02 billion by 2016

Psoriasis- $2.4 billion in 2010, estimates of over $7.3 billion by 2015

Eczema- $2.5 billion in 2014

ViaDerma sees the use of CBD’s along with our Proprietary transdermal delivery system for the treatment and continuing studies look very promising and demonstrate efficacy in terms of treating several unrelated diseases. “We are enthusiastic about the results we have achieved to date in terms of the anecdotal feedback we have received from the medical community,” said Dr. Christopher Otiko, ViaDerma’s founder and CEO.

About ViaDerma, Inc.

ViaDerma, Inc. (OTC PINK: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma’s lead product, TetraStem™, uses an innovative transdermal delivery method that allows for application of active ingredients in a topical form. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. For more information, please visit: www.viadermalicensing.com.

Add a Comment to this Post

comments